LCS
CRDF icon

Levin Capital Strategies’s Cardiff Oncology CRDF Stock Holding History

Levin Capital Strategies’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-139
Closed -$57K – 352
2015
Q3 		$57K Buy
+139
New +$72.7K ﹤0.01% 360

Other funds holding CRDF

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Levin Capital Strategies's CRDF Position: Q4 2015 in Review

Levin Capital Strategies sold out of Cardiff Oncology (CRDF) in Q4 2015, closing a stake of 139 shares — an estimated $57K sold.

Levin Capital Strategies first reported a position in CRDF in Q3 2015 and held it in 1 quarter. The position peaked at $57K in Q3 2015. 66 funds tracked by Wall St. Rank hold CRDF as of Q4 2015.

  • Levin Capital Strategies reported no remaining Cardiff Oncology position as of Q4 2015 after selling out during the quarter.
  • Levin Capital Strategies sold 139 Cardiff Oncology shares in Q4 2015, an estimated $57K.
  • Levin Capital Strategies first reported a position in Cardiff Oncology in Q3 2015 and held it in 1 quarter.
  • Levin Capital Strategies's Cardiff Oncology position peaked at $57K in Q3 2015.
  • 66 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2015.

Based on Levin Capital Strategies's 13F filing for Q4 2015, filed 10 Feb 2016.